What is it about?
Romidepsin, a clinically available anti-cancer drug, can potently activate a latent DNA virus known as Epstein-Barr virus (EBV) into lytic cycle in EBV-associated epithelial cancer cells such as nasopharyngeal carcinoma, resulting in cell death of the cancer. An anti-viral drug, ganciclovir, can enhance the cell death caused by romidepsin, representing a novel form of virus-targeted treatment for virus-associated cancers.
Featured Image
Why is it important?
As EBV is harbored in every cancer cell of EBV-associated cancers. Strategy that can target the virus can render specific therapeutic effects towards the cancer cells with low systemic toxicities.
Perspectives
A continual effort of my group to develop novel virus targeted approaches to treat EBV-associated cancers, using clinically relevant drugs.
Dr Alan KS CHIANG
The University of Hong Kong
Read the Original
This page is a summary of: Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir, International Journal of Cancer, August 2015, Wiley,
DOI: 10.1002/ijc.29698.
You can read the full text:
Contributors
The following have contributed to this page
